Nongastric marginal zone B-cell lymphoma: a prognostic model from a retrospective multicenter study.
The International Prognostic Index (IPI) and Follicular Lymphoma Prognostic Index (FLIPI) are used as prognostic indices for NHL and indolent lymphoma. However, marginal zone B-cell lymphoma (MZL) evidences a distinctive clinical presentation and a natural course; thus, in this study, we attempted to devise an adequate prognostic index for MZL. Two-hundred and five patients diagnosed with MZL were retrospectively reviewed. After analysis of the prognostic factors, progression-free survival (PFS), and overall survival (OS), we constructed a prognostic index of MZL (MZLPI) via the summation of each factor. We then compared PFS and OS with IPI, FLIPI, and MZLPI. According to our multivariate analysis, nodal MZL, ECOG performance > or = 2, and advanced stage were composed of MZLPI. MZLPI was grouped as follows: score 0 as a low-risk group, score 1 as an intermediate risk group, and score 2 as a high-risk group. The PFS curve, according to MZLPI results, evidenced a more discriminated pattern than IPI and FLIPI, and this was especially true in the intermediate risk group. In OS, MZLPI (P=0.0007) evidenced a more discriminated pattern than IPI (P=NS) or FLIPI (P=0.0044). MZLPI, which is constructed of relatively simple factors, may represent a useful prognostic index for the prediction of PFS and OS in MZL, and may also be used as a substitute for IPI or FLIPI.
Oh
Sung Yong
SY
Department of Internal Medicine, Dong-A University College of Medicine, 3-1 Dongdaeshin-Dong, Seo-Gu, Busan, Republic of Korea.
Kwon
Hyuk-Chan
HC
Kim
Won Seog
WS
Park
Yeon Hee
YH
Kim
Kihyun
K
Kim
Hyun Jung
HJ
Kwon
Jung Mi
JM
Lee
Jeeyun
J
Ko
Young Hye
YH
Ahn
Yong Chan
YC
Oh
Suk Joong
SJ
Lee
Soon Il
SI
Bang
Soo Mee
SM
Kim
Jung Han
JH
Park
Jinny
J
Ryoo
Baek-Yeol
BY
Lee
Seung-Sook
SS
Kim
Ho Young
HY
Park
Keunchil
K
Kim
Hyo-Jin
HJ
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015331:Cohort Studies; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000175:diagnosis* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome